Church & Dwight heads into its July 28 earnings report with analyst sentiment nudging higher, shorts sitting at a modest but slowly growing level, and options traders tilted decisively toward calls.
The most immediate prompt is from Wells Fargo. Analyst Chris Carey raised his price target on CHD to $110 from $105 on Tuesday — restoring the cut he made in early April during the tariff-driven market selloff — while holding his Overweight rating. That move puts Wells Fargo's target comfortably above the current price of $98.95. RBC Capital separately sits at $114 with an Outperform, reiterating that level as recently as June 1. On the other side, JPMorgan and UBS both hold Neutral ratings with targets clustered near $99-$100 — essentially flat to current levels — and Barclays remains the clear bear in the room with an Underweight and an $80 target. The Street consensus target of roughly $103 implies limited near-term upside from here, with the bull-bear split unusually wide.
Short positioning is modest but worth tracking into the print. SI has climbed about 7% over the past month to roughly 4.4% of the free float — not crowded by any measure, but the direction of travel is upward. The borrow market offers no particular signal either way: cost to borrow is running below 0.5%, and availability is enormous at over 2,600% of short interest, meaning there are roughly 26 shares available to borrow for every one currently lent out. Bears face no friction in establishing or adding to positions. The ORTEX short score holds around 42, placing CHD in the bottom third of the universe on short pressure — positioning looks more cautious than aggressive.
Options traders are leaning bullish, and emphatically so. The put/call ratio has dropped to 0.23, more than a full standard deviation below its 20-day average of 0.26, near the lowest reading of the past year (the 52-week low is 0.16). Call volume is dominating the order book. That skew is consistent with either genuine bullish conviction ahead of earnings, or hedgers already positioned and no longer needing protection — either way it reinforces the directional tilt toward the upside camp.
The Street's debate on CHD has a familiar shape. Bulls point to brand resilience — Arm & Hammer, OxiClean — volume growth holding up against private-label pressure, and the capacity to pursue bolt-on acquisitions in high-growth categories. Bears flag the Vitamin business as an ongoing drag, heavy US concentration as a structural risk, and valuation that leaves little room for disappointment: the stock trades at roughly 24.8x trailing earnings and 16.8x EV/EBITDA, both near the top of consumer staples peers. CL and PG — the two closest correlates — both gained around 2-3% on the week, broadly in line with CHD's 2.1% move, suggesting no idiosyncratic divergence in sentiment across the group. KMB was the week's standout at nearly +4.4%.
The last earnings print — May 1 — dropped CHD 4.3% the day of the release and a further 3.7% over the following five days. That reaction is the natural reference point for the July 28 date. With Wells Fargo's freshly lifted target at $110 and the options market tilted toward calls, the question heading into the quarter is whether volume trends in core categories have continued to hold, and whether the Vitamin headwind has begun to ease or has deepened further.
See the live data behind this article on ORTEX.
Open CHD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
